Skip to main content

Table 2 G6PD deficiency measured by the rapid diagnostic test CareStart™, and reactive G6PD enzyme activity of samples collected from RDT deficient individuals, measured by fluorescence spectrophotometry

From: Heterogeneity of G6PD deficiency prevalence in Mozambique: a school-based cross-sectional survey in three different regions

  CareStart G6PD deficiency Reactive G6PD activitya
Total Deficient % (95% CI) χ2 test
p value
Total Median U/gHg (range) Kruskal–Wallis
p value
Pemba
 Females 509 33 6.5 (4.3–9.1) 0.03* 31 0.7 (0.2–0.7) 0.08*
 Males 386 41 10.6 (7.5–14.1) 40 0.7 (0.2–0.7)
 All 895 74 8.3 (6.5–10.1) 71 0.7 (0.2–0.7)
Mocuba
 Females 252 37 14.7 (10.3–19.1) 0.21* 33 1.4 (0.6–2.1) 0.08*
 Males 249 47 18.9 (14.0–24.1) 40 2.1 (0.6–2.1)
 All 501 84 16.8 (13.5–20.1) 73 1.4 (0.6–2.1)
Manhiça
 Females 390 55 14.1 (10.6–18.1) 0.65* 53 0.7 (0.5–2.5) 0.03*
 Males 240 37 15.4 (10.8–20.1) 36 0.6 (0.5–2.5)
 All 630 92 14.6 (11.8–17.1) 89 0.7 (0.5–2.5)
Total
 Females 1151 125 10.9 (9.1–13.1) 0.02δ 117 0.7 (0.2–2.5) 0.57δ
 Males 875 125 14.3 (12.0–17.1) 116 0.7 (0.2–2.5)
 All 2026 250 12.3 (10.9–14.1) <0.001δ 233 0.7 (0.2–2.5) <0.001δ
  1. * Chi Square or Kruskal–Wallis tests performed to assess the association between gender and G6PD Deficiency for each Area separately
  2. δChi Square or Kruskal–Wallis tests performed to assess the association between study area or gender and G6PD Deficiency Overall
  3. aREA assessed only for samples collected form G6PD Deficient Individuals as determined by the CareStart RDT